CoLucid Pharmaceuticals (NASDAQ: CLCD) and Bristol-Myers Squibb (NYSE:BMY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares CoLucid Pharmaceuticals and Bristol-Myers Squibb’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CoLucid Pharmaceuticals N/A N/A N/A ($3.43) -13.57
Bristol-Myers Squibb $19.43 billion 5.26 $4.46 billion $2.54 24.57

Bristol-Myers Squibb has higher revenue and earnings than CoLucid Pharmaceuticals. CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.


This table compares CoLucid Pharmaceuticals and Bristol-Myers Squibb’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CoLucid Pharmaceuticals N/A -83.51% -70.62%
Bristol-Myers Squibb 20.56% 32.41% 14.66%


Bristol-Myers Squibb pays an annual dividend of $1.56 per share and has a dividend yield of 2.5%. CoLucid Pharmaceuticals does not pay a dividend. Bristol-Myers Squibb pays out 61.4% of its earnings in the form of a dividend. Bristol-Myers Squibb has increased its dividend for 7 consecutive years.

Institutional and Insider Ownership

64.2% of CoLucid Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Bristol-Myers Squibb shares are held by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CoLucid Pharmaceuticals and Bristol-Myers Squibb, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CoLucid Pharmaceuticals 0 3 1 0 2.25
Bristol-Myers Squibb 1 8 9 0 2.44

CoLucid Pharmaceuticals presently has a consensus target price of $47.83, suggesting a potential upside of 2.80%. Bristol-Myers Squibb has a consensus target price of $63.92, suggesting a potential upside of 2.42%. Given CoLucid Pharmaceuticals’ higher probable upside, equities analysts clearly believe CoLucid Pharmaceuticals is more favorable than Bristol-Myers Squibb.


Bristol-Myers Squibb beats CoLucid Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Receive News & Ratings for CoLucid Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals and related companies with's FREE daily email newsletter.